• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Viemed Healthcare Inc.

    2/14/24 4:51:42 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care
    Get the next $VMD alert in real time by email
    SC 13G 1 tm243309d19_sc13g.htm SC 13G

     

     

    UNITED STATES

     SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    Viemed Healthcare, Inc.

    (Name of Issuer)

     

    Common Shares, no par value

    (Title of Class of Securities)

     

    92840H400 

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    ¨ Rule 13d-1(c)

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Continued on following pages

    Page 1 of 7 Pages

     

     

     

     

     

    CUSIP NO. 92840H400 Page 2 of 7

     

    CUSIP No.  92840H400
    (1) Names of reporting persons Nantahala Capital Management, LLC
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization MA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 1,952,368
    (7) Sole dispositive power 0
    (8) Shared dispositive power 1,952,368
    (9) Aggregate amount beneficially owned by each reporting person 1,952,368
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 5.1%
    (12) Type of reporting person (see instructions) IA

     

     

     

     

    CUSIP NO. 92840H400 Page 3 of 7

     

    CUSIP No.  92840H400
    (1) Names of reporting persons Wilmot B. Harkey
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 1,952,368
    (7) Sole dispositive power 0
    (8) Shared dispositive power 1,952,368
    (9) Aggregate amount beneficially owned by each reporting person 1,952,368
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 5.1%
    (12) Type of reporting person (see instructions) HC

     

     

     

     

    CUSIP NO. 92840H400 Page 4 of 7

     

    CUSIP No.  92840H400
    (1) Names of reporting persons Daniel Mack
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 1,952,368
    (7) Sole dispositive power 0
    (8) Shared dispositive power 1,952,368
    (9) Aggregate amount beneficially owned by each reporting person 1,952,368
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 5.1%
    (12) Type of reporting person (see instructions) HC

     

    Item 1(a). Name of Issuer:
       
      Viemed Healthcare, Inc. (the “Issuer”).
       
    Item 1(b). Address of the Issuer's Principal Executive Offices:
       
      625 E. KALISTE SALOOM RD., LAFAYETTE, LA 70508
       
    Item 2(a). Name of Person Filing
       
     

    Nantahala Capital Management, LLC (“Nantahala”)

    Wilmot B. Harkey

    Daniel Mack (together the “Reporting Persons”)

       
    Item 2(b). Address of Principal Business Office or, if None, Residence:
       
     

    130 Main St. 2nd Floor

    New Canaan, CT 06840

     

    Item 2(c). Citizenship:
       
     

    Nantahala is a Massachusetts limited liability company.

    Each of Messrs. Harkey and Mack is a citizen of the United States of America.

       
    Item 2(d).

    Title of Class of Securities:

     

     

    Common Shares, no par value (the “Shares”).

     

     

     

     

    CUSIP NO. 92840H400 Page 5 of 7

     

    Item 2(e).

    CUSIP Number:
     

     

    92840H400

     

    Item 3.

    If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     

    (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

     

    (g) x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).

     

    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 4.

     

    Ownership:

       
    Item 4(a).

    Amount Beneficially Owned:

     

    As of December 31, 2023, Nantahala may be deemed to be the beneficial owner of 1,952,368 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares.

       
    Item 4(b).

    Percent of Class:

     

    As of December 31, 2023, each of the Reporting Persons may be deemed to be the beneficial owner of 5.1% of the total number of Shares outstanding.

     

     

     

     

    CUSIP NO. 92840H400 Page 6 of 7

     

    Item 4(c). Number of shares as to which such person has:
       
     

    Nantahala Capital Management, LLC

     

      (i) Sole power to vote or direct the vote 0
      (ii) Shared power to vote or to direct the vote 1,952,368
      (iii) Sole power to dispose or to direct the disposition of 0
      (iv) Shared power to dispose or to direct the disposition of 1,952,368
     

     

    Each of Messrs. Harkey and Mack

     

      (i) Sole power to vote or direct the vote 0
      (ii) Shared power to vote or to direct the vote 1,952,368
      (iii) Sole power to dispose or to direct the disposition of 0
      (iv) Shared power to dispose or to direct the disposition of 1,952,368
           
    Item 5. Ownership of Five Percent or Less of a Class:
       
      This Item 5 is not applicable.
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person:
       
      This Item 6 is not applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:
       
      Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in §240.13d-1(b)(1)(ii)(E). See Item 4(a).
       
    Item 8. Identification and Classification of Members of the Group:
       
      This Item 8 is not applicable.
       
    Item 9. Notice of Dissolution of Group:
       
      This Item 9 is not applicable.
       
    Item 10. Certification:
       

     

    By signing below each Reporting Person certifies that, to the best of such person's knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

     

     

     

    CUSIP NO. 92840H400 Page 7 of 7

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete, and correct.

     

    Date:  February 14, 2024 NANTAHALA CAPITAL MANAGEMENT, LLC
         
      By: /s/ Taki Vasilakis
      Taki Vasilakis
      Chief Compliance Officer
         
      /s/ Wilmot B. Harkey
      Wilmot B. Harkey
         
      /s/ Daniel Mack
      Daniel Mack

     

     

     

    Get the next $VMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VMD

    DatePrice TargetRatingAnalyst
    11/3/2021$13.00 → $9.00Outperform
    RBC Capital
    More analyst ratings

    $VMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Viemed Healthcare Inc. (Amendment)

      SC 13D/A - VIEMED HEALTHCARE, INC. (0001729149) (Subject)

      2/15/24 9:27:58 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G/A filed by Viemed Healthcare Inc. (Amendment)

      SC 13G/A - VIEMED HEALTHCARE, INC. (0001729149) (Subject)

      2/15/24 9:27:32 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G filed by Viemed Healthcare Inc.

      SC 13G - VIEMED HEALTHCARE, INC. (0001729149) (Subject)

      2/14/24 4:51:42 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care

    $VMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Viemed Healthcare to Present and Host 1x1 Investor Meetings at the 15th Annual East Coast Ideas Investor Conference on June 11th in New York

      LAFAYETTE, La., June 03, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, today announced it will present at the East Coast IDEAS Investor Conference on Wednesday June 11, 2025 at The Westin Times Square in New York, NY. Viemed's presentation is scheduled to begin at 11:30am ET. The presentation is webcast and can be accessed through the conference host's main website: https://www.threepartadvisors.com/east-coast and in the investor relations section of the Company's website: http://viemed.com/investors. ABOUT VIEMED HEALTHCARE, INC. Viemed is an

      6/3/25 8:00:00 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Viemed Healthcare Announces First Quarter 2025 Financial Results

      LAFAYETTE, La., May 07, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months ended March 31, 2025, and updated guidance for the full year ending December 31, 2025. Operational highlights (all dollar amounts are USD): Net revenues for the quarter ended March 31, 2025 were $59.1 million, representing an increase of $8.5 million, or 17%, over net revenues reported for the comparable quarter ended March 31, 2024. Net income attributable to Viemed for t

      5/7/25 4:45:00 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Viemed Executes Diversification Strategy With $26 Million Acquisition of Home Equipment Provider in Illinois

      LAFAYETTE, La., May 06, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, announced that it has entered into a definitive agreement to acquire Illinois-based Lehan's Medical Equipment ("Lehan"), a healthcare company offering home medical equipment with specialties in respiratory care and women's health. "Operating for nearly 80 years, Lehan has established a well-deserved reputation for its expertise in home medical equipment with a particular emphasis on women's health and a deep commitment to community engagement," said Viemed Chief

      5/6/25 8:30:00 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care

    $VMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Viemed Executes Diversification Strategy With $26 Million Acquisition of Home Equipment Provider in Illinois

      LAFAYETTE, La., May 06, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, announced that it has entered into a definitive agreement to acquire Illinois-based Lehan's Medical Equipment ("Lehan"), a healthcare company offering home medical equipment with specialties in respiratory care and women's health. "Operating for nearly 80 years, Lehan has established a well-deserved reputation for its expertise in home medical equipment with a particular emphasis on women's health and a deep commitment to community engagement," said Viemed Chief

      5/6/25 8:30:00 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Viemed Announces Acquisition of Majority Interest in HomeMed, Forging Partnership With East Alabama Health

      LAFAYETTE, La., April 02, 2024 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced the finalization of its strategic partnership with East Alabama Health ("EAH"), providing Viemed with the controlling interest of East Alabama HomeMed, LLC ("HomeMed"). HomeMed provides home medical equipment services to patients within the EAH network as well as those in the surrounding areas of Eastern Alabama. "We are thrilled to join forces with the exceptional team at East Alabama Health to deliver best-in-class home medical services to their patients and expand Home

      4/2/24 9:00:00 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Viemed Healthcare Announces Voting Results From Its Annual General Meeting of Shareholders

      LAFAYETTE, La., June 13, 2023 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD, TSX:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, today announced the voting results from its annual general meeting of shareholders held on June 13, 2023 (the "Meeting") in Lafayette, Louisiana. The total number of shares represented in person or by proxy at the Meeting was 27,309,147, representing 71.33% of the total issued and outstanding shares in the capital of the Company. Election of Directors The eight candidates nominated for election to the Company's Board of Directors (the "Board") and listed in the Company's m

      6/13/23 5:00:00 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care

    $VMD
    SEC Filings

    See more
    • Viemed Healthcare Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - VIEMED HEALTHCARE, INC. (0001729149) (Filer)

      6/5/25 5:15:49 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 10-Q filed by Viemed Healthcare Inc.

      10-Q - VIEMED HEALTHCARE, INC. (0001729149) (Filer)

      5/7/25 4:50:18 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Viemed Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - VIEMED HEALTHCARE, INC. (0001729149) (Filer)

      5/7/25 4:47:49 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care

    $VMD
    Financials

    Live finance-specific insights

    See more

    $VMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $VMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Viemed Healthcare Announces First Quarter 2025 Financial Results

      LAFAYETTE, La., May 07, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months ended March 31, 2025, and updated guidance for the full year ending December 31, 2025. Operational highlights (all dollar amounts are USD): Net revenues for the quarter ended March 31, 2025 were $59.1 million, representing an increase of $8.5 million, or 17%, over net revenues reported for the comparable quarter ended March 31, 2024. Net income attributable to Viemed for t

      5/7/25 4:45:00 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Viemed Healthcare Announces First Quarter 2025 Earnings Conference Call Details

      LAFAYETTE, La., April 22, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, today announced that it will host its First Quarter 2025 Earnings Conference Call on Thursday, May 8, 2025, at 11:00 a.m. EDT. Interested parties may participate in the call by dialing: (866) 682-6100 (US Toll-Free) +1 (862) 298-0702 (International) Live Audio Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=0dOJVhdb Following the live call, a replay will be available in the Investor Relations section of the Company's website at www.viemed.com. ABOUT VIE

      4/22/25 4:30:00 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Viemed Healthcare Announces Record 2024 Financial Results

      LAFAYETTE, La., March 10, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months and year ended December 31, 2024, and issued its guidance for the full year ending December 31, 2025. Fourth Quarter and Full Year Operational Highlights (all dollar amounts are USD): Net revenues for the quarter ended December 31, 2024 reached a new Company record of $60.7 million representing an increase of $10.0 million, or 20%, over net revenues reported for the comparable quarter ended Decembe

      3/10/25 5:00:00 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Heltz Sabrina bought $19,977 worth of shares (2,820 units at $7.08), increasing direct ownership by 7% to 41,040 units (SEC Form 4)

      4 - VIEMED HEALTHCARE, INC. (0001729149) (Issuer)

      5/14/24 5:25:11 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Director Smokoff Timothy sold $91,364 worth of shares (11,865 units at $7.70), decreasing direct ownership by 13% to 79,786 units (SEC Form 4)

      4 - VIEMED HEALTHCARE, INC. (0001729149) (Issuer)

      3/17/25 4:42:59 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Chief Operating Officer Zehnder William Todd converted options into 35,791 shares, covered exercise/tax liability with 8,147 shares and returned $74,089 worth of shares to the company (8,948 units at $8.28), increasing direct ownership by 7% to 273,973 units (SEC Form 4)

      4 - VIEMED HEALTHCARE, INC. (0001729149) (Issuer)

      1/31/25 3:28:06 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Chief Financial Officer Fitzgerald Trae converted options into 13,060 shares, covered exercise/tax liability with 2,962 shares and returned $27,034 worth of shares to the company (3,265 units at $8.28), increasing direct ownership by 9% to 82,994 units (SEC Form 4)

      4 - VIEMED HEALTHCARE, INC. (0001729149) (Issuer)

      1/31/25 3:27:56 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care

    $VMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RBC Capital reiterated coverage on Viemed Healthcare with a new price target

      RBC Capital reiterated coverage of Viemed Healthcare with a rating of Outperform and set a new price target of $9.00 from $13.00 previously

      11/3/21 9:01:34 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Royal Bank of Canada initiated coverage on Viemed Healthcare with a new price target

      Royal Bank of Canada initiated coverage of Viemed Healthcare with a rating of Outperform and set a new price target of $13.00

      3/11/21 8:08:09 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • RBC Capital initiated coverage on Viemed Healthcare with a new price target

      RBC Capital initiated coverage of Viemed Healthcare with a rating of Outperform and set a new price target of $13.00

      3/5/21 8:11:16 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care